Latest news with #DamianGarde
Bloomberg
4 days ago
- Business
- Bloomberg
Bristol-Myers to Pay $11 Billion to License Cancer Drug
Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as competition intensifies in an area of oncology that seeks to harness the immune system to attack tumors. Bloomberg's Damian Garde reports. (Source: Bloomberg)
Bloomberg
24-04-2025
- Business
- Bloomberg
Merck Expects $200 Million Tariff Hit Amid Gardasil Fallout
Merck expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US and China. The company's first-quarter results beat estimates, with sales of $15.5 billion and adjusted earnings of $2.22 per share. Merck expects to launch an easier-to-use version of Keytruda later this year and is counting on new medicines to offset the impending decline of Keytruda. Merck's sales of Gardasil vaccine have fallen 41% in the first quarter, but the company is counting on new medicines, including a easier-to-use version of Keytruda, to offset the decline. Bloomberg's Damian Garde reports. (Source: Bloomberg)
Bloomberg
11-03-2025
- Health
- Bloomberg
Trump's CDC Pick Is Pushing Vaccine-Autism ‘Lie,' Senator Says
By and Damian Garde Save Dave Weldon, President Donald Trump's pick to run the country's top public health agency, said in a recent meeting that he still believes the debunked theory that the childhood immunization schedule may be linked to autism, according to a Democratic senator in attendance. Weldon told Senator Patty Murray that children may be exposed to toxic levels of mercury through the US government's recommended immunization schedule, even though mercury hasn't been used in childhood vaccines for nearly 25 years in the US. Weldon's comments indicate his long-held vaccine skepticism hasn't changed despite ample evidence contradicting this view.
